Immupharma Regulatory News (IMM)

18 Dec 2007 12:51

Immupharma PLC18 December 2007 For Immediate Release 18 December 2007 ImmuPharma PLC Directors' Dealing Powe Capital increases stake in ImmuPharma to over 5% ImmuPharma PLC (LSE:IMM), ("ImmuPharma" or the "Company"), announces today thatPowe Capital, through its funds Modulus Europe and Tensor Europe, has increasedits stake in ImmuPharma from 3.12% to 5.59% through a purchase, on 14 December2007, of 1,800,000 existing ordinary shares of 10 pence each in the Company fromthe Trusts of two of ImmuPharma's founders and Directors, Richard Warr andDimitri Dimitriou. The subsequent interests are as follows: Shares Price per Subsequent beneficial Subsequent percent purchased share holding interest Modulus 1,540,000 £0.73 3,808,127 5.23%Europe Tensor 260,000 £0.73 260,000 0.36%Europe Shares Price per Subsequent beneficial Subsequent percent placed share holding interestRichard Warr 900,000 £0.73 11,878,968 16.32%(1) DimitriDimitriou(2) 900,000 £0.73 11,878,969 16.32% (1) Ordinary shares of £0.10 held by Louvre Trustees where the Warr family has abeneficial interest. (2) Ordinary shares of £0.10 held by Louvre Trustees where the Dimitriou familyhas a beneficial interest. Richard Warr, ImmuPharma's Chairman said: "Powe Capital has been a longstandingsupporter and shareholder of ImmuPharma. We are delighted by the confidence theyhave shown in the Company by increasing their stake to over 5%." For further information please contact: ImmuPharma PLC: Richard Warr, Chairman +44 20 7152 4080 Dimitri Dimitriou, Chief Executive Officer +44 20 7152 4080 Buchanan Communications +44 20 7466 5000 Lisa Baderoon Rebecca Skye Dietrich Panmure Gordon & Co Andrew Burnett +44 151 243 0963 This information is provided by RNS The company news service from the London Stock Exchange